Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team...
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors...
WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences...
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development...
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take...
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases...
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.115 | -3.15500685871 | 3.645 | 4.34 | 3.49 | 296970 | 3.74333352 | CS |
| 4 | -1.44 | -28.9738430584 | 4.97 | 5.1 | 3.48 | 310450 | 4.04779865 | CS |
| 12 | -1.5 | -29.8210735586 | 5.03 | 5.86 | 3.48 | 334625 | 4.48386863 | CS |
| 26 | -1.5 | -29.8210735586 | 5.03 | 5.86 | 3.48 | 334625 | 4.48386863 | CS |
| 52 | -1.5 | -29.8210735586 | 5.03 | 5.86 | 3.48 | 334625 | 4.48386863 | CS |
| 156 | -1.5 | -29.8210735586 | 5.03 | 5.86 | 3.48 | 334625 | 4.48386863 | CS |
| 260 | -1.5 | -29.8210735586 | 5.03 | 5.86 | 3.48 | 334625 | 4.48386863 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
